- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02834936
A Clinica Study of Pyrotinib in Patients of Advanced Non-Small Cell Lung Cancer With HER2 Mutation
A Phase 2 Clinica Study: Efficacy and Safety of Pyrotinib in Patients of Advanced Non-Small Cell Lung Cancer With HER2 Mutation
This study is designed to evaluate the efficacy and safety of Pyrotinib in patients of advanced pre-treated Non-small cell lung cancer With HER2 Mutation.
To observe objective response rate (ORR) of pyrotinib in NSCLC With HER2 Mutation. To observe Progression free survival (PFS). To assess the overall survival (OS).
A secondary aim is to obtain safety information.
To explore the relationship between biomarkers and the toxicity/efficacy of Pyrotinib.
Study Overview
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Beijing, China
- Recruiting
- HR-BLTN-II-NSCLC Investigational Site
-
Contact:
- Jiangang Yu
- Phone Number: 18036618602
- Email: yujiangang@shhrp.com
-
Changsha, China
- Recruiting
- HR-BLTN-II-NSCLC Investigational Site
-
Contact:
- Jiangang Yu
- Phone Number: 18036618602
- Email: yujiangang@shhrp.com
-
Guangzhou, China
- Not yet recruiting
- HR-BLTN-II-NSCLC Investigational Site
-
Hangzhou, China
- Recruiting
- HR-BLTN-II-NSCLC Investigational Site
-
Contact:
- Jiangang Yu
- Phone Number: 18036618602
- Email: yujiangang@shhrp.com
-
Harbin, China
- Recruiting
- HR-BLTN-II-NSCLC Investigational Site
-
Contact:
- Jiangang Yu
- Phone Number: 18036618602
- Email: yujiangang@shhrp.com
-
Nanjing, China
- Recruiting
- HR-BLTN-II-NSCLC Investigational Site
-
Contact:
- Jiangang Yu
- Phone Number: 18036618602
- Email: yujiangang@shhrp.com
-
Shanghai, China
- Not yet recruiting
- HR-BLTN-II-NSCLC Investigational Site
-
Contact:
- Jiangang Yu
- Phone Number: 18036618602
- Email: yujiangang@shhrp.com
-
Suzhou, China
- Recruiting
- HR-BLTN-II-NSCLC Investigational Site
-
Contact:
- Jiangang Yu
- Phone Number: 18036618602
- Email: yujiangang@shhrp.com
-
Wuhan, China
- Not yet recruiting
- HR-BLTN-II-NSCLC Investigational Site
-
Zhengzhou, China
- Recruiting
- HR-BLTN-II-NSCLC Investigational Site
-
Contact:
- Jiangang Yu
- Phone Number: 18036618602
- Email: yujiangang@shhrp.com
-
-
Shanghai
-
Shanghai, Shanghai, China, 200433
- Recruiting
- Shanghai Pulmonary Hospital
-
Contact:
- Caicun Zhou, M. D.
- Email: caicunzhoudr@126.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- ECOG performance status of 0 to 1.
- Life expectancy of more than 3 months.
- At least one measurable lesion exists.(RECIST 1.1).
- Histologically or cytologic confirmed Non-small cell lung cancer, Phase IIIB or IV according to IASLC 2009.
- Failed prior therapies.(RECIST 1.1).
- Confirmed HER2 mutation by Central Laboratory。
- More than one prior Platinum based chemotherapy for advanced and/or metastatic, or recurrent NSCLC in neoadjuvant or adjuvant chemotherapy.
Required laboratory values including following parameters:
ANC: ≥ 1.5 x 10^9/L; Platelet count: ≥ 90 x 10^9/L; Hemoglobin: ≥ 90 g/L; Total bilirubin: ≤ 1.5 x upper limit of normal (ULN); ALT and AST: ≤2 x ULN or ALT and AST: ≤5x ULN for patients with liver metastasis; BUN and Cr: ≤1.5 x ULN; creatine clearance rate: ≥ 50 mL/min; LVEF: ≥ 50%; QTcF: < 470 ms for female and < 450 ms for male.
- Signed informed consent
Exclusion Criteria:
- Previous therapy with other HER2 inhibitors.
- History of severe hypersensitivity reactions to the excipients of the trial drugs.
- Have clinically significant cavity effusion,such as pleural effusion、 pericardial effusion or ascites and require clinical intervention
- Active brain metastases
- Other malignancy within the past (including primary brain tumor or Leptomeningeal tumor), other than basal cell skin cancer or carcinoma in situ of the cervix
- Persistence of clinically relevant therapy related toxicities from previous therapy (greater than Common Terminology Criteria for Adverse Event(CTCAE) 4.0 grade 1)
- Treatment with surgery, chemotherapy, radiotherapy or other target therapy within the past 4 weeks before start of therapy
- Uncontrolled hypertensin,diabetes.
- unstable angina, history of myocardial infarction in the past 6 months, congestive heart failure>NYHA II, serious cardiac arrhythmia
- Active infection
- Variety of factors that affect the oral medication (such as unable to swallow, chronic diarrhea, bowel obstruction and other gastrointestinal disorders or abnormalities
- History of immunodeficiency, including HIV-positive, suffering from other acquired, congenital immunodeficiency disease, or history of organ transplantation.
- Subjects had any heart disease, including: (1) angina; (2) requiring medication or clinically significant arrhythmia; (3) myocardial infarction; (4) heart failure; (5) Any heart diseases judged by investigator as unsuitable to participate in the trial.
- Female patients who are pregnancy, lactation or women who are of childbearing potential tested positive in baseline pregnancy test.
- Known history of neurological or psychiatric disease, including epilepsy or dementia.
- Treatment in another clinical trial within the past 4 weeks before start of therapy
- Any of the other conditions of which researchers believe that the patient is not fit to take part in the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: pyrotinib treatment
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Objective Response Rate (ORR)
Time Frame: tumor assessment every 6-9 weeks after the initiation of pyrotinib, up to 24 months
|
tumor assessment every 6-9 weeks after the initiation of pyrotinib, up to 24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression Free Survival (PFS)
Time Frame: up to 24 months
|
up to 24 months
|
|
Incidence and Intensity of Adverse Events
Time Frame: From signing informed consent document until 28 days after the last drug administration
|
Number of Participants with treatment related Adverse Events as Assessed by CTCAE v4.0
|
From signing informed consent document until 28 days after the last drug administration
|
Collaborators and Investigators
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HR-BLTN-Ⅱ-NSCLC
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non Small Cell Lung
-
WindMIL TherapeuticsBristol-Myers SquibbTerminatedNSCLC | Lung Cancer | Lung Cancer Metastatic | Lung Cancer, Non-small Cell | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non Small Cell Lung Cancer MetastaticUnited States
-
University of California, San FranciscoAstraZenecaActive, not recruitingStage IIIA Non-Small Cell Lung Cancer | Stage I Non-Small Cell Lung Cancer | Stage IA Non-Small Cell Lung Cancer | Stage IB Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Cancer | Stage IIB Non-Small Cell Lung CancerUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Bristol-Myers SquibbCompletedStage IIIA Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage I Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung Cancer | Stage IA Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung Carcinoma | Non-Squamous Non-Small...United States
-
National Cancer Institute (NCI)TerminatedStage IIIA Non-small Cell Lung Cancer | Stage IA Non-small Cell Lung Cancer | Stage IB Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung CancerUnited States
-
University of Wisconsin, MadisonNational Cancer Institute (NCI)CompletedStage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Extensive Stage Small Cell Lung Cancer | Recurrent Small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Healthy, no Evidence of Disease | Limited Stage Small Cell Lung... and other conditionsUnited States
-
AIO-Studien-gGmbHBristol-Myers Squibb; Eli Lilly and Company; Merck Sharp & Dohme LLC; Pfizer; Gilead... and other collaboratorsRecruitingSmall-cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non-small Cell Lung Cancer Stage I | Metastatic Non-small Cell Lung Cancer (NSCLC) | Non Small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer Stage IIGermany
-
Alexander ChiNot yet recruitingNon-small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Stage I | Non-small Cell Carcinoma | Non-small Cell Lung Cancer Stage IIChina
-
Karen KellyBristol-Myers Squibb; National Cancer Institute (NCI); TransgeneCompletedStage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer | Stage I Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung CancerUnited States
-
Stanford UniversityAstraZenecaRecruitingNon-small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Stage I | Non-small Cell Lung Cancer Stage IIUnited States
-
Ohio State University Comprehensive Cancer CenterActive, not recruitingStage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung CancerUnited States
Clinical Trials on pyrotinib
-
Hunan Cancer HospitalJiangsu HengRui Medicine Co., Ltd.Not yet recruitingHER2-positive Breast CancerChina
-
Jiangsu HengRui Medicine Co., Ltd.Cancer Institute and Hospital, Chinese Academy of Medical SciencesCompleted
-
Peking Union Medical CollegeUnknownBreast Cancer | HER2 Gene MutationChina
-
Tongji UniversityUnknownNon-small Cell Lung CancerChina
-
Tianjin Medical University Cancer Institute and...UnknownNon Small Cell Lung CancerChina
-
Henan Cancer HospitalJiangsu HengRui Medicine Co., Ltd.Active, not recruitingMetastatic Breast CancerChina
-
RemeGen Co., Ltd.Not yet recruitingNon-small Cell Lung CancerChina
-
Second Affiliated Hospital, School of Medicine,...Zhejiang Cancer Hospital; First Affiliated Hospital of Zhejiang University; Sir... and other collaboratorsUnknownColorectal CancerChina
-
The First Affiliated Hospital with Nanjing Medical...First Affiliated Hospital of Wenzhou Medical UniversityRecruiting
-
xuexin heNot yet recruitingHER2-positive Breast Cancer